# Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma

> **NCT07428252** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Institute of Oncology Ljubljana** · enrollment: 150 (estimated)

## Conditions studied

- Metastatic Malignant Melanoma

## Interventions

- **DRUG:** PD-1 inhibitors
- **DRUG:** PD-1 and CTLA-4 inhibitors

## Key facts

- **NCT ID:** NCT07428252
- **Lead sponsor:** Institute of Oncology Ljubljana
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-01
- **Primary completion:** 2024-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-02-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07428252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07428252, "Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07428252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*